Clinical trials: Tumor Immunity
Anesthesia, Breast Cancer
The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.
Even decade ago it was believed that the choice method of anesthesia did not affect the course of the oncological process, but recent evidence has begun to emerge that inhalation anesthesia vs TIVA is associated with a higher…
- Trial name
- TeMP (NCT04800393)
- Testing
- Sevoflurane, Propofol
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Moscow Clinical Scientific Center
Myeloma, Lymphoma
Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia
A prospective study in which hematological oncology patients who were vaccinated against RSV will undergo a blood test to assess their immune response to the vaccine.
- Conditions
- Myeloma, Lymphoma, CLL, Myelodysplastic Syndrome
- Trial name
- NCT06944119
- Where
- Israel
- Volunteers
- 250 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Prostate Cancer
High Impact Training to Patients with Prostate Cancer and Bone Metastases
HIP is a randomized controlled trial. The aim is investigate the effect, safety and feasibility of brief, high-impact exercise targeting bones in patients with prostate cancer and bone metastases.
- Trial name
- HIP (NCT06259279)
- Testing
- High intensity high impact exercise intervention
- Where
- Denmark
- Volunteers
- 102 people
- Sponsor
- Copenhagen University Hospital at Herlev
Solid Cancers
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy
This is a translational, open-label, multi-site, prospective cohort study aiming to identify and to monitor immunological biomarkers associated with therapeutic response to immune checkpoints blockade (ICB), in patients with…
- Trial name
- MINER (NCT03514368)
- Testing
- Patients treated with immune checkpoint blockade
- Where
- 3 sites in France
- Volunteers
- 770 people
- Sponsor
- Institut Claudius Regaud
Oncology, COVID-19
Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic
This registry will allow to evaluate the correlation of the incidence and evolution of associated symptoms of infection of COVID-19 with the biological and clinical parameters in patients followed in Oncology during the COVID-19…
- Trial name
- OBVIONCO (NCT04437719)
- Testing
- Obvio-19 app
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Breast Cancer
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
The purpose of this research study is to evaluate Immunotherapy with a peptide vaccine and Programmed Death Ligand 1 (PD-L1) inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer.
- Trial name
- NCT02826434
- Testing
- PVX-410, Durvalumab, Hiltonol
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Prostate Cancer
Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome
Exposure to radiation can impact immune cells that are present in the blood, such as lymphocytes. It is hypothesized that larger radiation fields and/or longer courses of radiation, result in greater decrease in immune cells.
- Trial name
- NCT03383107
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Weill Medical College of Cornell University
Hepatocellular Carcinoma (HCC)
Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab
Increased pyruvate-to-lactate conversion is a hallmark of HCC metabolism. In parallel, activation of pro-inflammatory immune cells triggers a metabolic switch towards anaerobic glycolysis.
- Trial name
- NCT06605664
- Testing
- Hyperpolarized 13C pyruvate MRI
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Melanoma (Skin), Melanoma in Situ
Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2
This study is meant to assess the use of intralesional IL-2 to modulate the immunological response to suspected melanoma, or melanoma in situ, in an effort to increase lymphocyte infiltration and decrease disease metastasis.
- Trial name
- IL-2 (NCT03233828)
- Testing
- Aldesleukin, Saline
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Carman Giacomantonio
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT04852822
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- 11 sites in United States
- Volunteers
- 350 people
- Sponsor
- University of Washington
EBV, Epstein-Barr Virus Infection
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
Background: Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s population.
- Conditions
- EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
- Trial name
- NCT06908096
- Testing
- EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Colorectal Neoplasms
Anesthetic Technique on Immune Response in Colorectal Cancer
Knowing the fact that the anesthetic substances can alter the immune response during the surgery, the purpose of the study is to evaluate the influence of two general anesthetic techniques - inhalation vs.
- Trial name
- T-IL-Co-ReCa (NCT01902849)
- Testing
- blood sampling for IL measurement
- Where
- Romania
- Volunteers
- 70 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Melanoma
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
To Determine the feasibility, compliance and adherence to PreFED intervention in resectable melanoma patients initiating neoadjuvant Ipi/Nivo.
- Trial name
- NCT06548789
- Testing
- Prebiotic Xnack Packouts
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Psychological Stress
Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response
The proposed investigation will conduct a randomized, clinical trial to test the efficacy of a cognitive behavioral stress management (CBSM) group intervention on immune response to vaccine and distress among women at elevated…
- Trial name
- NCT00121160
- Testing
- Cognitive Behavioral Stress Management (CBSM) group intervention
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
T-cell Lymphoma, B-Cell Lymphoma
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
This protocol is being submitted to consolidate, update, and expand two previously approved protocols (77-C-0066 and 82-C-0044) into a single protocol.
- Conditions
- T-cell Lymphoma, B-Cell Lymphoma, ATL, Myeloma
- Trial name
- NCT00001582
- Where
- United States
- Volunteers
- 902 people
- Sponsor
- National Cancer Institute (NCI)
Medullary Thyroid Cancer (MTC)
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Background: GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA.
- Trial name
- NCT01856920
- Testing
- GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- NantCell, Inc.
Bladder Cancer, Prostate Cancer
Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment
This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.
- Conditions
- Bladder Cancer, Prostate Cancer, Kidney Cancer
- Trial name
- NCT06762925
- Testing
- No Interventions
- Volunteers
- 450 people
- Sponsor
- Xijing Hospital
Surgery, Renal Cancer
Effects of Anesthesia on Immunity in Cancer
The aim of the study is a comparative study of the cellular immunity response of patients operated on for kidney cancer under total intravenous and inhalational anesthesia.
- Trial name
- NCT03514550
- Testing
- Propofol, Sevoflurane, Epidural block
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Liver Metastasis Colon Cancer
Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer
The goal of this pilot clinical trial is to learn about the combination of immune boosting drugs and irreversible electroporation (IRE) in patients with colon cancer that has spread to the liver (metastasis).
- Trial name
- NCT06047015
- Testing
- IRE plus checkpoint inhibitor, IRE plus Checkpoint Inhibitor plus CpG-ODN
- Volunteers
- 12 people
- Sponsor
- University of Saskatchewan
Pancreatic Cancer
Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer
This protocol will study the impact of Irreversible electroporation (IRE) on immune response in patients diagnosed with unresectable pancreatic cancers smaller than 5.0 cm.
- Trial name
- NCT02343835
- Testing
- NanoKnife LEDC System
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou